Nektar Therapeutics 3Q 2026: Revenue $9.39M, EPS ($1.63) — 10-Q Summary

Nektar Therapeutics reported 3Q 2026 revenue of $9.39M, down 20% YoY, and a net loss of $55.65M, up 57% YoY. Higher R&D and G&A expenses drove the loss, partly offset by interest income and restructuring benefits. The company advanced Phase 3 trials for rezpegaldesleukin and reported $952.9M in cash and investments.

Original reporting
Published Nov 13, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nektar Therapeutics 3Q 2026: Revenue $9.39M, EPS ($1.63) — 10-Q Summary — source image
Decision brief

The 30-second read

$NKTRBearishMed
01

Why it matters

The earnings miss may trigger short‑term sell pressure, but strong cash position and potential litigation recovery provide upside catalysts.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for traders tracking biotech earnings momentum.

03

What to watch

Lilly verdict award of $90M could offset some loss if upheld on appeal.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

Nektar Therapeutics filed its Q3 2026 10‑Q, reporting a revenue decline and larger net loss, with ongoing Phase 3 trials and a pending litigation award.

Company-level read

Ticker impact

$NKTRBearishHigh confidence
Context

10-Q shows Q3 revenue down 20% YoY to $9.39M and net loss widening 57% to $55.65M.

Expected impact

likely downside as market prices in weaker revenue and higher loss

Evidence & confidence

Revenue decline and loss expansion are material negative surprises for a micro‑cap biotech.

Market effects

Biotech sector may see modest pullback on earnings disappointment.

US biotech investors may reduce exposure to early‑stage therapeutic firms.

Limited; primarily affects US‑listed biotech investors.

Counterpoint

Cash runway of $952.9M suggests sufficient liquidity to fund upcoming Phase 3 trials, potentially supporting a rebound.

Key entities

  • Nektar Therapeutics

    US‑listed biotech (NASDAQ: NKTR) reporting Q3 2026 results.

Related articles

$NKTRMed

Nektar (NKTR) Q3 2026 Earnings Call Transcript

Nektar (NKTR) discussed its Q3 2026 earnings, highlighting the potential of REZPEG, a novel treatment for atopic dermatitis and alopecia areata. The company reported positive phase II data and plans for phase III trials, aiming for a broad label. REZPEG targets multiple inflammatory pathways, addressing unmet needs in the $30B+ U.S. eczema market. Nektar expects top-line data in 2028 and a BLA filing by late 2029.

$NKTRLow

In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics reported $952.9 million in cash and…

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD. In conjunction with its third quarter financial results announced yesterday, November 12, 2026, Nektar Therapeutics (the “Company”) reported $952.9 million in cash and investments in marketable securities as of September 30, 2026. Consistent with its prio

$NKTRMedAI 8/10

What Nektar Therapeutics (NKTR) Said on Its Q3 Earnings Call

Nektar Therapeutics (NKTR) reported Q3 earnings, highlighting clinical trial progress and updated financial guidance. The company expects to complete enrollment in three studies by January 2028 and report one-year data from the REZOLVE-AD study in Q1 2027. Nektar plans additional studies for alopecia, vitiligo, and type 1 diabetes. The company raised its cash outlook to over $840M for 2026, with Q3 net loss of $56M. Research and development expenses are projected to increase in Q4.

$NKTRMed

Nektar Therapeutics Announces Third Quarter 2026 Financial Results

NEKTAR THERAPEUTICS (NKTR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Nektar Therapeutics Announces Third Quarter 2026 Financial Results SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update